Strikingly, the combination of anti-PD1 inhibitor with the anti-DPP4 inhibitor sitagliptin in the xenograft model induced a complete tumor regression, emphasizing the improved therapeutic efficacy of ICIs when combined with inhibitors of genes targeted by HCC-specific ncRNAs [106]. Here, DPP4 is linked to hepatocellular carcinoma.